FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 57 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $533,000 | -35.7% | 160,096 | -41.2% | 0.00% | – |
| Q3 2019 | $829,000 | +298.6% | 272,429 | +212.2% | 0.00% | – |
| Q2 2019 | $208,000 | -37.9% | 87,272 | -2.3% | 0.00% | – |
| Q1 2019 | $335,000 | +28.8% | 89,300 | +23.2% | 0.00% | – |
| Q4 2018 | $260,000 | -58.1% | 72,474 | -33.1% | 0.00% | – |
| Q3 2018 | $620,000 | +49.0% | 108,300 | +30.2% | 0.00% | – |
| Q2 2018 | $416,000 | +111.2% | 83,210 | +116.7% | 0.00% | – |
| Q1 2018 | $197,000 | -7.9% | 38,400 | +7.8% | 0.00% | – |
| Q4 2017 | $214,000 | -9.3% | 35,606 | -30.2% | 0.00% | – |
| Q2 2017 | $236,000 | -76.3% | 50,987 | -74.7% | 0.00% | – |
| Q1 2017 | $996,000 | +424.2% | 201,200 | +1075.6% | 0.00% | – |
| Q4 2016 | $190,000 | +123.5% | 17,114 | +27.3% | 0.00% | – |
| Q2 2016 | $85,000 | – | 13,448 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $24,530,000,000 | 3.64% |
| Opaleye Management Inc. | 950,000 | $4,873,000 | 1.39% |
| DSC Advisors, L.P. | 1,187,604 | $6,092,000 | 1.28% |
| DAFNA Capital Management LLC | 335,500 | $1,721,000 | 0.84% |
| Vivo Capital, LLC | 855,000 | $4,386,000 | 0.62% |
| Stonepine Capital Management, LLC | 129,756 | $666,000 | 0.36% |
| Eversept Partners, LP | 107,500 | $551,475 | 0.26% |
| Tekla Capital Management LLC | 930,398 | $4,773,000 | 0.19% |
| Perceptive Advisors | 1,117,324 | $5,732,000 | 0.16% |
| Crestline Management, LP | 217,670 | $1,117,000 | 0.14% |